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ABSTRACT
Background and aim: Intramucosal gastric adenocarcinoma of the well-
moderately differentiated type only exhibits lymph node metastasis in extremely 
rare cases. We encountered such case and investigated both the lymphangiogenic 
properties and somatic mutations in the cancer to understand the prometastatic 
features of early-stage gastric cancer.
Methods: We quantitatively measured the density of lymphatic vessels and 
identified mutations in 412 cancer-associated genes through next-generation target 
resequencing of DNA extracted from tumor cells in a formalin-fixed and paraffin-
embedded tissue. Functional consequence of the identified mutation was examined 
in vitro by means of gene transfection, immunoblot, and the quantitative real-time 
polymerase chain reaction assay.
Results: The intramucosal carcinoma was accompanied by abundant lymphatic 
vessels. The metastatic tumor harbored somatic mutations in NBN, p.P6S, and PAX8, 
p.R49H. The PAX8R49H showed significantly higher transactivation activity toward E2F1 
than the wild-type PAX8 (P< 0.001).
Conclusions: Our data suggest that increased lymphangiogenesis and somatic 
mutations of NBN and/or PAX8 could facilitate lymph node metastasis from an 
intramucosal gastric carcinoma. These findings may potentially inform evaluations of the 
risk of developing lymph node metastasis in patients with intramucosal gastric cancer.
INTRODUCTION
An endoscopic resection is recommended as 
a standard treatment (absolute indication) for early 
gastric carcinomas that fulfill the following criteria: a 
differentiated-type adenocarcinoma without ulcerative 
findings, of which the depth of invasion is clinically 
diagnosed as cT1a and the diameter is ≤ 2 cm [1]. This 
recommendation is based on the rare occurrence of 
lymph node (LN) metastasis, which is reported to be 
0.12% (3/2402) or 0% (0/6456), in patients with early 
gastric cancer fulfilling the above criteria [1–3]. Despite 
the rare occurrence of LN metastasis, published reports 
have emphasized the importance of careful evaluation of 
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LN state by using computed tomography (CT) because 
if a LN metastasis is found, a surgical resection with 
lymphadenectomy should be performed instead of the 
endoscopic resection [2, 4]. Hence, mechanistic insights 
into LN metastasis from early gastric cancer could provide 
clues for improving the present criteria for the absolute 
indication of endoscopic resection for early gastric 
cancer. We obtained a rare opportunity to explore a case 
of intramucosal gastric adenocarcinoma with synchronized 
LN metastasis. In this case, we performed a quantitative 
lymphatic vessel density evaluation, targeted resequencing 
of 412 cancer-associated genes by next-generation 
sequencing technology, and a subsequent functional 
analysis for a mutated gene.
RESULTS
Patient characteristics and clinical course
A 68-year-old woman, with a history of eradicated 
Helicobacter pylori infection, suffered from transient 
epigastralgia. The patient underwent upper gastrointestinal 
endoscopy, which elucidated an irregular mucosal lesion 
in the gastric angle (Figure 1A). A biopsy revealed a 
tubular adenocarcinoma of the well-differentiated type. 
Carcinoembryonic antigen (CEA) and carbohydrate 
antigen 19-9 (CA19-9) levels were 8.5 ng/ml and 50 U/ml, 
respectively. Although the lesion seemed to be confined 
within the gastric mucosa and to fulfill the absolute 
indication of endoscopic resection, a suspicious LN 
metastatic lesion (23 mm diameter) beside the left gastric 
artery was noted on a CT scan (Figure 1B). A laparoscopic 
tumor biopsy revealed that the tumor was an enlarged 
LN with tubular adenocarcinoma that was histologically 
similar to the gastric tumor (Figure 1C). Positron emission 
tomography/CT showed no apparent uptake except in 
the LN tumor. Thus, the patient was diagnosed to have 
an early gastric cancer with a regional LN metastasis 
and underwent the standard distal gastrectomy with D2 
lymph node dissection. After surgery, CEA and CA19-
9 levels normalized. The patient underwent no adjuvant 
chemotherapy and has remained in good health without 
any signs of recurrence or other malignant tumors for 39 
months (most recent follow-up).
Pathological findings
A pathological examination identified 4 independent 
lesions, 1–4 mm in diameter, in close vicinity to each other 
at the gastric angle (Figure 2A). The lesions consisted of 
well-differentiated tubular adenocarcinomas confined 
within the mucosal layer without any apparent ulceration 
(Figure 2B, Supplementary Figure 1). There was no scar 
formation that could suggest segregation of an originally 
existing tumor into 4 cancerous lesions. The histological 
features were identical to those of the metastatic 
adenocarcinoma in the LN along the lesser curvature 
(Figure 1C, 2B).
Evaluation of lymphatic vessels
Formalin-fixed and paraffin-embedded (FFPE) 
tissue sections were immunohistochemically stained with 
anti-D2-40 antibody. D2-40-positive lymphatic vessels 
were particularly dense in the lamina propria of the 
intramucosal tubular adenocarcinoma in the primary tumor. 
The dense lymphatic vessels showed irregular shapes with 
collapsing compared to those in normal mucosa (Figure 
2C–2E). Lymphatic vessel density was evaluated semi-
quantitatively as described by Pak et al [5]. Intratumoral 
lymphatic vessel density (I-LVD), peritumoral lymphatic 
vessel density (P-LVD), and control lymphatic vessel 
density (C-LVD) were 72.3 ± 4.5, 10.7 ± 3.8, and 10.7 ± 
8.3, respectively. The I-LVD was significantly higher than 
P-LVD (P< 0.001) and C-LVD (P< 0.001). Moreover, 
I-LVD in this patient was strikingly higher than the mean 
values reported by Pak et al. for node-negative cases, 
11.26± 3.84, and N3 cases, 14.16 ± 5.00 [5].
Figure 1: Preoperative findings. (A) Endoscopy showed irregular mucosa in the lesser curvature of the gastric angle with ill-defined 
margins from surrounding atrophic mucosa. (B) Computed tomography showed an irregular oval tumor of 23 mm diameter beside the left 
gastric artery (arrow). (C) Laparoscopic biopsy of the intra-abdominal tumor revealed a metastatic tubular adenocarcinoma in the lymph 
node. Hematoxylin and eosin (H&E) staining, original magnification, ×100.
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Somatic mutations
We prepared DNA from microdissected FFPE tissue 
samples of the primary intramucosal gastric carcinoma, 
the metastatic LN carcinoma, and a normal tissue, and 
performed target resequencing using an Ion Proton System 
(Thermo Fisher Scientific, Carlsbad, CA, USA). We 
employed two panels of target genes to cover the known 
commonly mutated genes in gastric cancer (Table 1) [6–8]. 
One panel was the IonAmpliSeq™ Comprehensive Cancer 
Panel (Thermo Fisher Scientific) that covered the coding 
exons of 409 cancer-associated genes, and the other was 
Figure 2: Gross and microscopic pathology of the surgically resected section of the stomach. (A) Four irregular mucosal 
lesions, each 1-4 mm in diameter, were located side by side in the lesser curvature (arrowheads). (B) The primary cancer consisted of tubular 
adenocarcinoma of the well-differentiated type confined within the mucosal layer without ulceration. H&E staining, original magnification, 
×100. (C-E) Images of immunohistochemical staining with anti-D2-40 antibody showed abundant lymphatic vessels in an intratumoral 
area (C) in contrast with scanty lymphatic vessels in a peritumoral area (D) and a portion of normal mucosa (E). All histological images 
were taken at the original magnification of ×200.
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Table 1: The list of target genes examined in panel sequencing
ABL1 CASC5 EGFR G6PD KLF6 MYCN PIM1 SH2D1A USP9X
ABL2 CBL EML4 GATA1 KRAS MYD88 PKHD1 SMAD2 VHL
ACVR2A CCND1 EP300 GATA2 LAMP1 MYH11 PLAG1 SMAD4 WAS
ADAMTS20 CCND2 EP400 GATA3 LCK MYH9 PLCG1 SMARCA4 WHSC1
AFF1 CCNE1 EPHA3 GDNF LIFR NBN PLEKHG5 SMARCB1 WRN
AFF3 CD79A EPHA7 GNA11 LPHN3 NCOA1 PML SMO WT1
AKAP9 CD79B EPHB1 GNAQ LPP NCOA2 PMS1 SMUG1 XPA
AKAP13 CDC73 EPHB4 GNAS LRP1B NCOA4 PMS2 SOCS1 XPC
AKT1 CDH1 EPHB6 GPR124 LTF NF1 POT1 SOX11 XPO1
AKT2 CDH11 ERBB2 GRM8 LTK NF2 POU5F1 SOX2 XRCC2
AKT3 CDH2 ERBB3 GUCY1A2 MAF NFE2L2 PPARG SRC ZNF384
ALK CDH20 ERBB4 HCAR1 MAFB NFKB1 PPP2R1A SSX1 ZNF521
APC CDH5 ERCC1 HIF1A MAGEA1 NFKB2 PRDM1 STK11
AR CDK12 ERCC2 HLF MAGI1 NIN PRKAR1A STK36
ARID1A CDK4 ERCC3 HNF1A MALT1 NKX2-1 PRKDC SUFU
ARID2 CDK6 ERCC4 HOOK3 MAML2 NLRP1 PSIP1 SYK
ARNT CDK8 ERCC5 HRAS MAP2K1 NOTCH1 PTCH1 SYNE1
ASXL1 CDKN2A ERG HSP90AA1 MAP2K2 NOTCH2 PTEN TAF1
ATF1 CDKN2B ESR1 HSP90AB1 MAP2K4 NOTCH4 PTGS2 TAF1L
ATM CDKN2C ETS1 ICK MAP3K7 NPM1 PTPN11 TAL1
ATR CEBPA ETV1 IDH1 MAPK1 NRAS PTPRD TBX22
ATRX CHEK1 ETV4 IDH2 MAPK8 NSD1 PTPRT TCF12
AURKA CHEK2 EXT1 IGF1R MARK1 NTRK1 RAD50 TCF3
AURKB CIC EXT2 IGF2 MARK4 NTRK3 RAF1 TCF7L1
AURKC CKS1B EZH2 IGF2R MBD1 NUMA1 RALGDS TCF7L2
AXL CMPK1 FAM123B IKBKB MCL1 NUP214 RARA TCL1A
BAI3 COL1A1 FANCA IKBKE MDM2 NUP98 RB1 TET1
BAP1 CRBN FANCC IKZF1 MDM4 PAK3 RECQL4 TET2
BCL10 CREB1 FANCD2 IL2 MEN1 PALB2 REL TFE3
BCL11A CREBBP FANCF IL21R MET PARP1 RET TGFBR2
BCL11B CRKL FANCG IL6ST MITF PAX3 RHOA TGM7
BCL2 CRTC1 FAS IL7R MLH1 PAX5 RHOH THBS1
BCL2L1 CSF1R FBXW7 ING4 MLL PAX7 RNASEL TIMP3
BCL2L2 CSMD3 FGFR1 IRF4 MLL2 PAX8 RNF2 TLR4
BCL3 CTNNA1 FGFR2 IRS2 MLL3 PBRM1 RNF213 TLX1
BCL6 CTNNB1 FGFR3 ITGA10 MLLT10 PBX1 ROS1 TNFAIP3
BCL9 CYLD FGFR4 ITGA9 MMP2 PDE4DIP RPS6KA2 TNFRSF14
BCR CYP2C19 FH ITGB2 MN1 PDGFB RRM1 TNK2
BIRC2 CYP2D6 FLCN ITGB3 MPL PDGFRA RUNX1 TOP1
(Continued)
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an Ion AmpliSeq™ Custom DNA Panel (Thermo Fisher 
Scientific) that was designed to cover the coding exons of 
RHOA and its regulatory molecules, AKAP13 and DLC1 
(Table 1). The mean coverage of each panel was 241.4 
and 4816.3 fold per amplicon, respectively. We identified 
somatic mutations in NBN, p.P6S, and PAX8, p.R49H, 
in the LN metastasis; however, we did not identify these 
mutations in the primary tumor (Table 2). These mutations 
were confirmed by Sanger sequencing (Figure 3A, 3B).
Functional analysis of PAX8, p.R49H
To determine a functional phenotype of the 
PAX8R49H, we compared transactivation activities 
between the wild type PAX8 and the mutant PAX8, 
i.e., PAX8R49H, toward E2F1 that was known to be a 
transcriptional target of paired box 8 (PAX8) [9]. We 
constructed expression vectors harboring the wild type 
PAX8 or the mutant PAX8, and transfected them into 
293T cells. The transfection induced an equivalent level 
of exogenous expression of encoded proteins as indicated 
by immunoblots in Figure 4A. Then, we measured 
transcriptions of E2F1 in the cells by the quantitative real 
time PCR assay. The result showed that the mutant PAX8 
induced a significantly increased level of transcription 
of E2F1 compared to the wild-type PAX8 as shown in 
Figure 4B (P < 0.001). These results indicate that the 
PAX8R49H may exhibit a gain-of-function phenotype 
compared to the wild-type PAX8.
DISCUSSION
Taking a molecular pathologic approach, we 
examined a peculiar case of gastric intramucosal 
adenocarcinoma with LN metastasis. The primary tumor 
seemed to fulfill the criteria for the absolute indication 
of ER; however, because of the LN metastasis, we 
performed a surgical resection with lymphadenectomy. 
In pathological examination, the primary tumor was 
accompanied by dense lymphatic vessels, and I-LVD 
proved to be particularly high. This finding suggests that 
the elevated level of lymphangiogenesis accompanying 
the adenocarcinoma could have increased the chances of 
primary cancer cells intravasating lymphatic vessels. LVD 
is known to be associated with LN metastasis in various 
human cancers [10]. As for gastric cancer, although 
differences in the pathological roles of I-LVD and P-LVD 
are still controversial, several reports showed that I-LVD 
was higher in tumors associated with LN metastasis [5, 11, 
12]. To the best of our knowledge, our case is the first to 
show that high I-LVD may facilitate LN metastasis even 
in a case of an intramucosal gastric carcinoma that seemed 
to meet the criteria for the absolute indication of ER. In the 
present case, the gastric cancer and metastatic LN were 
surgically resected because the swollen LN detected by 
CT was proven to be a metastasis by laparoscopic biopsy 
before surgery. This demonstrates that careful evaluation 
of LN state using CT is important, as was previously 
reported [4]. When LN metastasis is not identifiable on 
CT, I-LVD could potentially be measured to assess the risk 
of metastasis after ER because I-LVD can be evaluated in 
the ER specimen.
Next, we investigated the coding exons of 412 
cancer-associated genes by next-generation sequencing. 
As the primary cancer was uncommonly multicentric 
localized adjacent to each other, which suggests the 
possibility of a pre-existing mutational accumulation 
in the atrophic gastric mucosa due to a history of H. 
pylori infection as previously reported [13], we avoided 
using noncancerous mucosa as a normal control 
sample for this analysis. The results indicated that 
the present prometastatic intramucosal gastric cancer 
with extraordinary LN metastasis did not harbor any 
common mutations for gastric cancer such as TP53, 
ARID1A, PIK3CA, CDH1, SMAD4, APC, KRAS, or 
RHOA or its regulatory molecules, AKAP13 and DLC1. 
Instead, the present case harbored somatic mutations 
in the LN metastasis: NBN, p.P6S, and PAX8, p.R49H. 
BIRC3 DAXX FLI1 JAK1 MRE11A PDGFRB RUNX1T1 TP53
BIRC5 DCC FLT1 JAK2 MSH2 PER1 SAMD9 TPR
BLM DDB2 FLT3 JAK3 MSH6 PGAP3 SBDS TRIM24
BLNK DDIT3 FLT4 JUN MTOR PHOX2B SDHA TRIM33
BMPR1A DDR2 FN1 KAT6A MTR PIK3C2B SDHB TRIP11
BRAF DEK FOXL2 KAT6B MTRR PIK3CA SDHC TRRAP
BRD3 DICER1 FOXO1 KDM5C MUC1 PIK3CB SDHD TSC1
BRIP1 DLC1 FOXO3 KDM6A MUTYH PIK3CD SEPT9 TSC2
BTK DNMT3A FOXP1 KDR MYB PIK3CG SETD2 TSHR
BUB1B DPYD FOXP4 KEAP1 MYC PIK3R1 SF3B1 UBR5
CARD11 DST FZR1 KIT MYCL1 PIK3R2 SGK1 UGT1A1
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Table 2: Annotations for somatic mutations of NBN and PAX8
Gene Position Exon Coding 
DNA
Amino 
acid
COSMIC 
ID
SIFT Polyphen2 
HDIV
Mutation 
Taster
GQ DP AF
NBN Chr8:90996774 1 c.16C>T p.P6S 1102345 tolerated 
(0.13)
benign 
(0.429)
disease 
causing 58 122 0.11
PAX8 Chr2:114004376 3 c.146G>A p.R49H - damaging (0)
Probably 
damaging 
(0.999)
disease 
causing 114 179 0.14
AF, allele frequency based on flow evaluator observation counts; DP, total read depth at the locus; GQ, genotype quality.
Figure 3: Somatic mutations in NBN and PAX8 identified in the present case. (A) Validation by Sanger sequencing showed 
single nucleotide substitution in NBN and PAX8 in the lymph node metastasis (arrow) but not in the primary tumor. (B) Functional domains 
(colored boxes) and mutated residues (arrows) in nibrin (NBN) and paired box 8 (PAX8).
Figure 4: Transactivation of E2F1 by PAX8. (A) Immunoblot of 293T cells transfected with the PAX8R49H-V5-His (PAX8 R49H), 
PAX8wild-type-V5-His (PAX8 WT), and pcDNA3.1/V5-His vector (Empty vector) probed with antibodies of anti-PAX8, anti-V5, and anti-beta 
actin. (B) The relative expression of E2F1 in each transfected 293T cells measured by the quantitative real-time PCR assay. The expression 
of E2F1 was normalized to the expression of GAPDH and analyzed by means of the 2−ΔΔCT method. An asterisk indicated P < 0.001.
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The identification of only a few mutated genes could 
be explained by the early stage of the cancer. Molecular 
pathologic information of such an early-stage cancer with 
an aberrant prometastatic nature can be a valuable source 
to help elucidate the mechanism of metastasis because 
analyzing such cases may lead to the identification of 
molecular alterations associated with metastasis in a small 
number of mutated genes.
NBN encodes nibrin (NBN), a member of the 
MRE11/RAD50 double-strand break repair complex 
[14]. A truncating mutation in NBN causes a defective 
response to DNA double-strand breaks, which results in 
an unstable genome and a predisposition to malignancies 
[15]. The mutated P6 residue of NBN is not located 
within any functional domains. However, the P6S 
mutation of NBN was identified in a patient with uterine 
corpus endometrioid carcinoma (COSM1102345 in the 
COSMIC database, http://cancer.sanger.ac.uk/cosmic). 
NBN, p.K653fs is reported to be identified in peritoneal 
metastasis of gastric cancer by whole-exome sequencing 
elsewhere [16]. Although functional impacts of NBNP6S are 
not known, the mutation could cause genomic instability 
or copy number variations.
PAX8 encodes paired box 8 (PAX8), a transcription 
factor required for the formation of thyroxine-producing 
follicular cells, of endodermal origin [17]. PAX8R49C has 
been identified as a somatic mutation in gastric cancer 
according to the COSMIC database (COSM4084322); 
however, PAX8R49H has not been reported. The R49 
residue of PAX8 is located within the paired box domain 
(Figure 3B), which may be the reason that PAX8R49H 
was predicted to be functionally damaging by some 
prediction programs, namely Polyphen-2 (http://
genetics.bwh.harvard.edu/pph2/), SIFT (http://sift.jcvi.
org/), and MutationTaster (http://www.mutationtaster.
org/). Missense mutations within the paired box domain, 
such as p.Q40P, p.S54G, p.C57Y, p.L62R, are known 
to cause congenital hypothyroidism, thyroid hypoplasia 
and aplasia, and/or kidney agenesis due to the loss of its 
transactivation effect [18–21]. PAX8 is expressed highly 
in the thyroid and kidney as well as slightly but evidently 
in gastric mucosa and gastric cancer (GEO10420251 and 
GEO95672775 in Gene Expression Omnibus Profiles, 
https://www.ncbi.nlm.nih.gov/geoprofiles). PAX8 is 
reported to be expressed in metastatic non-small cell lung 
cancers and to promote cell migration via interaction 
with MET and RON [22].
By our experiments testing a transactivating 
function of PAX8 toward E2F1, we found that the 
PAX8R49H was able to show a gain-of-function phenotype 
in transactivation of E2F1 compared to the wild type 
PAX8. E2F transcription factor 1 (E2F1) encoded by 
E2F1 is well known for its tumor suppressive role 
in conjunction with retinoblastoma protein 1 (RB1), 
however, it is also known to play some promoting 
roles in cancer as reported to promote an epithelial-
mesenchymal transition (EMT) by transactivating 
FOXL2 in gastric cancer cells, which may be associated 
with increased LN metastasis in patients with gastric 
cancer [23]. Thus, our result and these compelling 
evidences suggest that PAX8R49H could have promoted 
EMT and subsequent LN metastasis via E2F1 in the 
present case.
In the present case, the somatic mutations were 
identified only in the metastatic LN tissue and not in 
the primary tumor. To explain this crucial observation, 
one can argue that the LN metastasis was not derived 
from the gastric adenocarcinoma but from elsewhere 
in other organs. However, we determined that the LN 
tumor was likely to be a metastasis of the intramucosal 
gastric carcinoma, which was cured by the surgical 
resection, through the following evidence: identical 
histology between the gastric tumor and the metastatic 
LN tumor, anatomical location of the metastatic LN, 
and the concerted decrease of elevated tumor markers. 
Moreover, the patient has not manifested any other 
malignant neoplasms for more than 3 years after surgery 
and no adjuvant chemotherapy. Alternatively, the 
failure of finding mutations in the intramucosal gastric 
carcinoma could be due to tumor heterogeneity, i.e., a 
small number of prometastatic clones in the primary 
tumor. A previous report indicated that a lethal metastatic 
clone of prostate cancer was derived from only a single 
small lesion in 36 sectioned blocks of the primary cancer 
[24]. Thus, it is likely that cells with a metastatic ability 
may have existed as just a tiny fraction in the primary 
tumor, which could not be detected. On the other hand, 
we could not exclude the possibility that the mutations 
occurred after metastasizing to the LN. Postmetastatic 
mutations could give advantages of survival and growth 
of cells in the metastatic site. Fractions of mutated calls 
were 11% and 14% in NBN and PAX8, respectively. 
This relatively minor fraction of mutated alleles may be 
due to 1) heterogeneity of cancer cells, 2) wild cancer 
cells derived from the collective dissemination of tumor 
clusters [25], or 3) normal lymphocytes with density 
drastically higher than that of the cancer cells, as shown 
in Figure 1C, meaning the ratio of cancer-derived DNA 
should be substantially lowered by contamination of 
even a small volume of peripheral lymphocytes. This 
could encourage the assumption that these mutations 
contributed to facilitation and/or development of LN 
metastasis, since they are more selected in the metastatic 
LN.
In conclusion, intramucosal gastric carcinoma that 
seemed to fulfill the criteria for the absolute indication 
of ER had a LN metastasis and thus was resected 
surgically. Increased lymphangiogenesis was observed 
in the primary tumor. Moreover, somatic mutations 
of NBN, p.P6S, and PAX8, p.R49H were observed in 
the metastatic tumor. The PAX8R49H showed a gain-of-
function phenotype in transactivation of E2F1. These 
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findings may serve not only to develop biomarkers 
and/or molecular therapeutic targets but also to revise 
current recommendation for ER resection of early 
gastric cancer.
MATERIALS AND METHODS
Ethics and informed consent
This study was approved by the ethical committee 
of Tokyo Women’s Medical University (protocol #272). 
Written informed consent was obtained from the patient 
for research and publication.
Quantitative analysis of lymphatic vessel density
FFPE tissue sections were immunohistochemically 
stained by using anti-D2-40 antibody (Covance Antibody 
Products, San Diego, CA, USA) and Autostainer Link 
48 (Dako, Glostrup, Denmark). Quantitative analysis of 
lymphatic vessel density (LVD) was performed by counting 
the D2-40 stained lymphatic vessels according to Pak et al 
[5]. Intratumoral (I)-LVD, Peritumoral (P)-LVD, and LVD 
in the normal control tissues (C-LVD) were counted.
Panel design for the next-generation sequencing
The Ion AmpliSeq™ Comprehensive Cancer Panel 
covering all coding exons of 409 cancer-associated genes 
and an Ion AmpliSeq™ Custom DNA Panel covering 
all coding exons of RHOA and its regulatory molecules, 
AKAP13 and DLC1, were used. In total, all coding exons 
of 412 genes were examined (Table 1).
Tissue dissection and DNA preparation
FFPE tissue samples from the primary gastric tumor, 
the metastatic LN tumor, and a normal portion of the stomach 
(submucosa or deeper area) were used for genetic analysis. 
Areas of adenocarcinoma found by microscopic observation 
were manually dissected. DNA was prepared with a QIAamp 
DNA FFPE Tissue Kit (Qiagen, Hilden, Germany). DNA 
from the metastatic LN tumor and normal gastric tissue were 
analyzed by next-generation sequencing. For the primary 
cancer, since each lesion was small, we mixed the DNA 
together and only analyzed it by Sanger sequencing.
Next-generation sequencing
Sequencing libraries were prepared using Ion 
AmpliSeq™ Library Kit 2.0 (Thermo Fisher Scientific) 
according to the manufacturer’s instruction. The quantity 
of DNA amplicons was evaluated using a High Sensitivity 
DNA kit (Agilent Technologies, Waldbronn, Germany). 
Sequencing was performed using an Ion Proton™ System 
(Thermo Fisher Scientific) according to the manufacturer’s 
instructions.
Variant calling and annotation
Data analyses were performed using the Ion Torrent 
Suite Software (version 5.0.3). After base calling, the 
reads were aligned against the reference human genome 
(hg19) using the TMAP algorithm within the Torrent Suite. 
Variants with Genome quality > 50 and an allele frequency 
> 10% were considered. For further single nucleotide 
polymorphism (SNP) analysis, only non-synonymous 
nucleotide exchanges were considered. SNPs reported to be 
> 1% in 1000G, ExAC or ESP6500si were dismissed. SNPs 
detected only in tumor tissues were counted. All somatic 
variations annotated were validated by Sanger sequencing.
Sanger sequencing
Genomic portions of somatic mutations 
were amplified by using paired primers of 
5′-GGTTACGCGGTTGCACGTCG-3′ and 5′-TCTGCCC 
TTACCTCCTGCCG-3′ for NBN and 5′-CTTTGTGAA 
TGGCAGACCTC-3′ and 5′-AAGGATCTTGCTGACGCA 
GC-3′ for PAX8. The amplified products were analyzed by 
Sanger sequencing, as described previously [26].
Cell culture
The human embryonic kidney 293T was obtained 
from the European Collection of Authenticated Cell 
Cultures (ECACC 12022001). The cells were cultured 
using Dulbecco’s Modified Eagle’s Medium (Sigma, 
St. Louis, MO, USA) with 10% fetal bovine serum in a 
humidified incubator at 37°C with 5% CO
2
.
Plasmid vectors
The wild-type PAX8 cDNA was amplified from 
a fetal kidney cDNA library (Agilent Technologies) 
by PCR using the KOD Plus DNA polymerase system 
(TOYOBO, Osaka, Japan). The paired primers 
used were as follows: forward 5′-TTTAAGCTT/
CCCCGGCGATGCCTCACAAC-3′, and reverse 
5′-TTTGAATTC/CAGATGGTCAAAGGCCGTGGC-3′. 
The amplified product was separated by agarose gel 
electrophoresis. A band corresponding to an equivalent 
molecular weight of PAX8 (NM_003466.3) was extracted, 
purified, and cloned into the pcDNA3.1/V5-His vector 
(Invitrogen, San Diego, CA, USA) at the HindIII and 
EcoRI sites to generate the wild-type PAX8-V5-His 
vector. The mutant PAX8 (p.R49H)-V5-His vector was 
generated by means of a site-directed mutagenesis 
technique using QuikChange II Site-Directed Mutagenesis 
Kit (Agilent Technologies) with following primers: 5′- 
GACGCGGAGCTGGTGAGAGATGTCGCAG-3′ and 
5′-CTGCGACATCTCTCACCAGCTCCGCGTC-3′ 
according to the manufacture’s instruction. Nucleotide 
sequences of the created plasmid vectors were confirmed 
by Sanger sequencing.
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Cell transfection
293T cells were seeded at a concentration of 
5×105 cells/well in 6-well plates 24 h before transfection. 
Transfection of each created plasmid vectors or the 
control pcDNA3.1/V5-His vector was performed using 
Lipofectamine 2000 Transfection Reagent (Thermo Fisher 
Scientific) according to the manufacturer’s instruction. 24 
h after transfection, cells were collected and proceeded to 
following immunoblotting and the quantitative real-time PCR 
assay. The experiment was performed twice in duplicate.
Immunoblotting
Collected cells were lysed in modified RIPA buffer 
containing 1×complete mini protease inhibitor cocktail 
(Sigma) and 1×PhosSTOP phosphatase inhibitor cocktail 
(Sigma). Cell extracts containing equal amounts of 
proteins were boiled in loading buffer, applied to 10-
20% polyacrylamide gradient gel, and separated by 
electrophoresis. Then the proteins were blotted onto a 
polyvinylidene difluoride membrane (ATTO, Tokyo, 
Japan). After blocking using the ECL Blocking Agent 
(Amersham Biosciences, Buckinghamshire, UK) for 1 h, 
the membrane was incubated with primary antibodies 
overnight. Primary antibodies used were the mouse 
monoclonal anti-PAX8 antibody (1:200 dilution) (Santa 
Cruz Biotechnology, Dallas, TX, USA), the mouse 
monoclonal anti-V5 antibody (1:5000 dilution) (Thermo 
Fisher Scientific), and the mouse monoclonal anti-β-
actin antibody (1:1000 dilution) (Sigma). The membrane 
was incubated with a secondary antibody for 1 h. The 
secondary antibody used was horseradish peroxidase-
conjugated anti-mouse immunoglobulin antibody 
(1:10000 dilution) (GE Healthcare, Buckinghamshire, 
UK). Signals were visualized using the ECL Prime 
Western Blotting Detection Reagent (Amersham 
Biosciences) and LAS 4000 Mini system (Fujifilm, 
Tokyo, Japan).
Quantitative real-time PCR assay
Total RNA was isolated from collected cells using 
RNeasy Mini kit (Qiagen, Hilden, Germany). cDNA 
synthesis was performed using High-Capacity cDNA 
Reverse Transcription Kit (Thermo Fisher Scientific). 
Pre-designed primer/probe sets for human PAX8 
(Hs00247586_m1) and E2F1 (Hs00153451_m1) in 
TaqMan gene expression assay system (Thermo Fisher 
Scientific) were used in the quantitative real-time PCR 
assay. GAPDH was used as an endogenous control. The 
analyses were performed by means of the 2−ΔΔCT method 
[27] upon the 7500 Real-Time PCR system (Thermo 
Fisher Scientific) according to the manufacture’s 
instruction. The experiment was performed twice in 
triplicate.
Statistical analyses
Continuous data are described as the mean and 
standard deviation and were compared using Tukey’s 
method.
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